Inhibitory effects of serum from sepsis patients on epithelial cell migration in vitro: a case control study

Henna Jaurila1,2*, Vesa Koivukangas1†, Marjo Koskela1†, Fia Gäädnäs1, Sirpa Salo3, Johanna Korvala2, Maija Risteli2, Toni Karhu4, Karl-Heinz Herzig4,5, Tuula Salo2,6‡ and Tero I. Ala-Kokko1‡

Abstract

Background: Sepsis delays wound re-epithelialization. In this study we explored the effect of human sepsis sera as well as the effects of cytokines, growth factors and exosomes of sepsis sera treated normal fibroblasts (NF) on keratinocyte migration and proliferation in vitro.

Methods: Serum samples were taken on days 1, 4, and 9 from 44 patients diagnosed with severe sepsis, and from 14 matching healthy controls. We evaluated the effects of sepsis serum with or without TNF-α, EGF, EGF receptor inhibitor or exosomes of sepsis sera treated NF on human keratinocyte (HaCaT) proliferation (BrdU assay), viability (MTT assay), and migration (horizontal wound healing model). Cytokine levels of sepsis and healthy sera were measured by multiplex assay. Comparisons between groups were carried out using SPSS statistics and P < 0.05 was considered significant.

Results: Severe-sepsis sera collected on days 1, 4, and 9 reduced keratinocyte proliferation by 6% (P = 0.005), 20% (P = 0.001), and 18% (P = 0.002), respectively, compared to control sera. Cell viability in cultures exposed to sepsis sera from days 4 and 9 was reduced by 38% (P = 0.01) and 58% (P < 0.001), respectively. Open-surface wounds exposed to sepsis sera from days 1 and 4 were larger than those exposed to sera from healthy controls (60 vs. 31%, P = 0.034 and 66 vs. 31%, P = 0.023, respectively). Exosomes of sepsis or healthy sera treated NF inhibited keratinocyte migration. We detected higher serum levels of cytokines TNF-α (5.7 vs. 0.7 pg/ml, P < 0.001), IL-6 (24.8 vs. 3.8 pg/ml, P < 0.001), IL-10 (30.0 vs. 11.9 pg/ml, P = 0.040), and VEGF (177.9 vs. 48.1 pg/ml, P = 0.018) in sepsis sera. Levels of EGF were significantly lower in sepsis sera than in that of healthy controls (6.5 vs. 115.6 pg/ml, P < 0.001). Sepsis serum supplemented with EGF 5 ng/ml and TNF-α in all concentrations improved keratinocyte migration.

Conclusions: Keratinocyte viability, proliferation and migration were reduced in severe sepsis in vitro. Exosomes from NF added in healthy or sepsis serum media inhibited keratinocyte migration. Decreased levels of EGF in sepsis sera may partially explain the delay of wound healing with severe-sepsis patients. Increased levels of TNF-α in sepsis sera do not explain diminished keratinocyte migration.

Keywords: Sepsis, Human serum, Migration, EGF, TNF-α, Exosome, HaCaT, In vitro

*Correspondence: Henna.jaurila@fimnet.fi
†Vesa Koivukangas and Marjo Koskela contributed equally to this work
‡Tuula Salo and Tero I. Ala-Kokko contributed equally to this work
1 Research Group of Surgery, Anesthesia and Intensive Care, Oulu University Hospital, P. O. Box 21, 90029 Oulu, Finland
2 Full list of author information is available at the end of the article

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Sepsis is defined as a dysregulated host response to outer pathogens leading to acute organ dysfunction [1, 2]. Skin is the main defensive barrier against outer pathogens. Disorders in skin function and wound healing during sepsis may lead to blistering and pressure ulcers that, in addition to surgery and invasive cannulations, compromise this defensive barrier [3]. Septic patients are prone to wound healing complications such as infections, delayed wound healing, fascial dehiscence and anastomotic leaks [4–9]. Septic patients’ predisposition to get spontaneous and iatrogenic wounds combined with impaired wound healing can lead to substantial functional and aesthetic, even life threatening problems. In our previous studies, skin collagen synthesis is proven to be diminished [10], the restoration of the epidermal barrier function to be delayed and wound blood flow increased in severe sepsis [8]. Wound re-epithelialization is delayed during sepsis, as demonstrated in rodent models [5, 7, 9] and in a human blister wound model [8]. Re-epithelialization is achieved via the migration and proliferation of keratinocytes from the edges of the wound. Cell migration is the rate-limiting event in the healing of skin wounds [11–13]. After injury, the wound repair process is initiated immediately by the release of growth factors and cytokines from the serum, which bind to receptors expressed by their target cells, and co-ordinate the re-epithelialization [3, 11, 13–16]. However, knowledge about cell migration and proliferation in human systemic sepsis is currently limited; sepsis wound-healing studies have been conducted only in animals [5, 7, 9]. The role of cytokines involved in wound healing in sepsis is somewhat unclear. Exosomes are secreted membrane enclosed vesicles containing proteins like Epithelial Growth Factor Receptor (EGFR) and nucleic acids [17–20]. Previously, exosomes were thought to only eliminate waste proteins from the cell, but now they are known to participate in intercellular communication and the transfer of functional genetic information thereby influencing the immune system [21, 22]. The role of exosomes in disease pathogenesis is under investigation. There have been some studies about exosomes in sepsis or in wound healing [23–29]. However, the effect of exosomes in migrating septic wounds is unknown.

Here we hypothesized that sera from septic patients could reduce the viability, proliferation, and in vitro wound healing (horizontal migration) of human skin keratinocytes. In order to elucidate a possible mechanism related to delayed wound healing, we measured cytokine levels and analyzed the distinctions between sera collected from septic patients and from healthy controls. In addition, different concentrations of selected cytokines and exosomes of sepsis and healthy sera treated gingival fibroblasts were added to in vitro keratinocyte wounds in order to explore their influence on cell migration. We expected to see some differences between exosomes from sepsis and healthy sera treated fibroblasts in keratinocyte migration.

Methods
Patients
This prospective observational case–control study of wound healing in severe sepsis was conducted in a 12-bed mixed-type intensive care unit (ICU) in Oulu University Hospital, Finland. This investigation is a sub-study of an earlier work that examined serum markers of collagen synthesis and degradation in severe sepsis [30]. The inclusion criterion was diagnosis of severe sepsis according to the American College of Chest Physicians/Society of Critical Care Medicine [1]. The exclusion criteria were: age under 18 years, malignancy, surgery not related to sepsis, surgery during the preceding 6 months, bleeding disorder, chronic hepatic or renal failure, and immunosuppressive or cortisone treatment not related to sepsis. Patients entered the study when the diagnosis of severe sepsis was met and within 48 h of the first identification of organ dysfunction. Patients were treated according to normal ICU protocol and current severe sepsis guidelines [31]. The study protocol was approved by The Regional Ethics Committee of the Northern Ostrobothnia Hospital District and written informed consent was obtained from each patient or their next of kin. The following information was collected from all patients: age, gender, type of ICU admission (medical or surgical), prevalence of septic shock, severity of underlying diseases on admission as assessed with the Acute Physiology and Chronic Health Evaluation II (APACHE II), and development of daily organ dysfunctions assessed with the daily Sequential Organ Failure Assessment (SOFA). Length of stay in the ICU and 30-day mortalities were recorded. Fourteen healthy sex- and age-matched volunteers served as controls.

Blood samples
Serum samples were collected after the first identification of sepsis-induced organ dysfunction. Samples were taken on days 1, 4, and 9 or until the patient was transferred to another unit/hospital or died. Serum samples from healthy controls were obtained once. The serum samples were immediately frozen and stored at −70 °C. In the cell-migration and proliferation experiments, individual serum samples were filtered and pooled using serum from each patient for final serum concentrations of 1% (in migration tests) or 10% (in proliferation tests) in serum free cell-culture medium. This strategy resulted in serum pools of 44 sepsis-serum samples on study day...
1. 36 samples on day 4, 22 samples on day 9, and a single pool of 14 healthy control serum samples. As an experimental control, we used 1 or 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA). Cytokine analysis employed undiluted, individual serum samples.

Cell lines
Human adult low-calcium high-temperature (HaCaT) cells are a spontaneously transformed human epithelial cell line from adult skin and maintain full epidermal differentiation capacity. These keratinocytes are immortalized and have unlimited growth potential, but still they are non-tumorigenic [32]. In our study, HaCaT cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml ascorbic acid, 250 ng/ml fungizone, and 1 mM sodium pyruvate (all from Sigma-Aldrich). Cells were derived from the freeze-down batch, which was thawed and grown to confluence in a 175-cm² flask. The cells were incubated at 37 °C, in 5% CO₂, and 95% humidity. The number of passages in all cell lines was less than 23.

Assay of keratinocyte (HaCaT) proliferation
To evaluate cell proliferation, HaCaT cells (10⁵ cells per well) were seeded, and cultured 24 h on 96-well plates. In each well, 100 μL of 10% test serum cocktail were pipetted onto HaCaT cells. After 24 h of incubation, cell proliferation was quantified via a colorimetric immunoassay of the incorporation of the thymidine analog 5-bromo-2′-deoxyuridine (BrdU) during DNA synthesis according to the manufacturer's instructions (Roche Diagnostics, Basel, Switzerland). Absorbance values were measured with a Victor3 V 1420 Multilabel Plate Counter (PerkinElmer, Waltham, MA, USA) at a wavelength of 544 nm. Assays were performed in triplicate and mean values were recorded.

Assay of keratinocyte (HaCaT) viability
HaCaT cells (10⁵ cells per well) were seeded and cultured 24 h on 96-well plates. In each well, 100 μL of 10% test serum cocktail were pipetted onto the cells, which were then incubated for 48 h. Cell viability was assayed with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) according to the manufacturer's instructions (Sigma-Aldrich). The number of living cells, evaluated via mitochondrial dehydrogenase activity, was measured with a Victor3 V 1420 Multilabel Plate Counter (PerkinElmer) at a wavelength of 544 nm. Assays were performed in triplicate and mean values were recorded.

Horizontal wound healing assay
Epithelial wound healing was investigated in vitro using an assay in which the wounds were made by plating the counted cells into commercial inserts (Ibidi GmbH, Munich, Germany) instead of scratching. In the migration tests, 1 × 10⁵ or 2 × 10⁵ cells per well were seeded and cultured on a 24-well plate in culture inserts. The silicone insert was removed after 24 h of incubation so that the resulting cell patch was split into two parts separated by a 500 μm cell-free zone. Cell-culture medium was replaced with serum free medium supplemented with 1% test serum samples. After 0, 12, 24, 36, and 48 h of incubation, cell migration (reduction in wound surface area) was recorded with a digital inverted microscope (Evos fl AMF-4302, AMG Life Technologies, Carlsbad, CA, USA) and an in vivo microscope camera (ICX285AL monochrome CCD, Sony, Tokyo, Japan). The plates were incubated at 37 °C between measurements. Open-wound areas on the digital images were measured using ImageJ [33]. There were 4–8 wounds in each group. We calculated the mean value of the remaining cell-free area at each time point in every group as well as the percentage by which the initial gap width decreased at each time point.

Exosome isolation and horizontal wound healing assay with exosomes
Human normal gingival fibroblasts (NF) [34] were used to isolate exosomes. Cells were maintained in DMEM supplemented with 10% heat-inactivated FBS, 1 mM sodium-pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml ascorbic acid and 250 ng/ml fungizone (all from Sigma-Aldrich) and incubated at 37 °C in 5% CO₂. For exosome isolation 500,000 cells were seeded in 175 cm² flasks and cultured 24 h in normal culture medium. The cells were washed once with phosphate buffered saline. Serum free medium supplemented with a 1% test serum pool of healthy or day one sepsis sera was added. Media was collected after 48 h, and centrifuged at 300×g for 2 min to remove dead cells. The supernatant was collected and stored at −70 °C until exosome isolation. Conditioned medium was thawed and ultracentrifuged at 10,000×g for 90 min at +4 °C in a swinging bucket TH-641 rotor (Thermo Fisher Scientific Inc., Waltham, MA, USA). The supernatant was removed to a fresh tube leaving 500 μl in the bottom of the previous tube. The supernatant was ultracentrifuged again at 100,000×g for 90 min to pellet exosomes. The supernatant was removed except for 200 μl and the pellet was re-suspended into this remaining supernatant. The protein concentration was measured with a DC Protein assay.
In the horizontal wound-healing assay 20 and 50 µg/ml of exosomes in serum free media were used both in healthy and sepsis groups. As controls we used 1% healthy and day one sepsis sera in serum free media and the horizontal wound healing assays were performed as described above. There were seven to eight wounds in each group.

**Assays of cytokines and growth factors**

The levels of serum cytokines and growth factors were measured by multiplex assay [35, 36] with a Milliplex Human Cytokine/Chemokine Magnetic Bead Panel (Millipore Corporation, Billerica, MA, USA) and a Bio-Plex 200 System (Bio-Rad Laboratories Pty Ltd, Hercules, CA, USA). Assays were performed according to the manufacturer’s instructions, as described previously [37]. Assay conditions were pre-optimized, standardized, and controlled to ensure optimal reproducibility. Results were calculated with BioPlex Manager Software 6.0 (Bio-Rad Laboratories). Serum levels of interleukin (IL)-4, IL-6, IL-10, tumor necrosis factor α (TNF-α), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and epithelial growth factor (EGF) were compared between samples from sepsis patients and healthy controls. The levels of cytokines and growth factors on day four were evaluated; at day four, the difference in keratinocyte migration and proliferation was most striking between model wounds exposed to sepsis sera or to healthy sera.

**Horizontal wound healing assay with EGF, TNF-α and EGFR inhibitor**

To explore keratinocyte migration, the horizontal wound healing assay was used in which 1% healthy or sepsis serum pools were supplemented with 5, 10 or 50 ng/ml of EGF or TNF-α (both from ProSpec, East Brunswick, NJ, USA) as well as 1, 10 or 50 µg/ml of EGFR inhibitor (Erbilux (cetuximab) 5 mg/ml, Merck, Germany). In this experiment, 1% healthy and sepsis serum samples without supplements served as controls. The migration test was performed three times and the number of wounds was between 4 and 8 in each group.

**Statistical analysis**

Data were entered into an SPSS database for analysis (SPSS version 21, IBM SPSS Statistics, Chicago, IL, USA). Summary measurements for variables were expressed as the median with 25th–75th percentiles or as the mean with standard deviation (SD). Comparisons between groups were performed using the independent-samples t test and the Mann–Whitney U test. Two-tailed P values were reported when possible. Differences were considered significant at P < 0.05.

**Results**

**Patients**

Between May 2005 and December 2006, 1361 patients were admitted to the ICU at Oulu University Hospital. Of these patients, 238 had severe sepsis and 66 met the inclusion criteria for this study. Written informed consent was obtained from 44 patients or their next of kin. Patient demographics have been presented previously [30]. Most of the 44 patients were male (66%) and there were 33 survivors (75%) on day 30 (Table 1). The control group consisted of 14 healthy age- and sex-matched volunteers, eight of them men (57%). The median age of the control group was 61 years (25th–75th percentile, 56–69 years).

**Keratinocyte proliferation and viability is diminished with sepsis sera**

In order to measure whether sepsis serum contains substances that affect cell proliferation and viability, HaCaT cells were incubated in the presence of healthy and sepsis serum. In the BrdU proliferation assay, the proliferation of cells exposed to day one sepsis serum was 6% lower (P = 0.005) compared with cells exposed to healthy serum, 20% lower (P = 0.001) in day 4 serum, and 18% lower (P = 0.002) in day 9 serum (Fig. 1). The MTT cell viability assay indicated that cells incubated with days 4 and 9 sepsis serum were significantly less viable than cells treated with healthy serum (38%, P = 0.01 and 58%, P < 0.001, respectively) (Fig. 2). Day-one viability was slightly increased by 13%; but this difference was not statistically significant (P = 0.115) (Fig. 2).

**Sepsis delays keratinocyte migration in the early days of the disease**

Effect of the sepsis serum on cell migration was tested using a wound-healing assay (Fig. 3a). The open wound

| Table 1 Summary demographics of the 44 study patients with severe sepsis | Severe sepsis (n = 44) |
| --- | --- |
| Male sex, n (%) | 29 (66%) |
| Age, years | 63 (56–71) |
| Surgical admission, n (%) | 25 (57%) |
| Septic shock, n (%) | 40 (91%) |
| APACHE II score on admission, points | 26 (22–31) |
| SOFA score on admission, points | 8 (6–12) |
| Length of stay in the ICU, days | 7 (4–12) |
| 30-day mortality, n (%) | 11 (25%) |

Variables are presented as frequencies with percentages or as medians with 25th to 75th percentiles

*Apache II acute physiology and chronic health evaluation II score
*SOFa sequential organ failure assessment
surface area in models exposed to healthy sera was 31% of the original wound gap (SD 27%) at 24 h and 22% (SD 27%) at 48 h. Wounds cultured with sepsis sera from days 1 and 4 had significantly larger wound surface areas (60%, SD 16%, P = 0.034 and 66%, SD 17%, P = 0.023, respectively) at 24 h, than wounds cultured with healthy sera (Fig. 3b). Wounds treated with sepsis sera from day nine did not significantly differ from those treated with healthy sera at 24 h (50%, SD 29%, P = 0.297). However, because the culture media was not changed, the cells started to starve. So, most likely, although the tendency remained the same, no statistically significant differences between healthy and sepsis sera samples were seen after 48 h incubation (day 1: 53%, SD 21%, P = 0.053; day 4: 46%, SD 34%, P = 0.263; day 9: 43%, SD 30%, P = 0.273) (Fig. 3b).

**Exosomes derived from healthy or sepsis sera treated fibroblasts reduce keratinocyte migration**

In the horizontal wound healing assay, we used 20 and 50 µg/ml of both healthy and sepsis exosomes in serum-free media. As controls, we used 1% healthy or sepsis sera. Keratinocytes in controls migrated as in previous experiments (Fig. 4). Migration in exosome treated wounds was significantly reduced compared to control wounds. Wounds with 20 or 50 µg/ml exosomes from healthy serum migrated significantly less than wounds with healthy control serum at 24 h (P = 0.018 and P = 0.015, respectively) and at 48 h (P = 0.025 and P = 0.021, respectively). Also wounds with 50 µg/ml exosomes from sepsis day 1 serum had a significant reduction in migration compared to sepsis control serum at 24 and 48 h (P = 0.027 and P = 0.037, respectively). Wounds with 20 µg/ml exosomes from sepsis day one serum migrated less compared to control serum either at 24 or 48 h, but the difference was not statistically significant (P = 0.083 and P = 0.132, respectively).

**Cytokine level differences between healthy and sepsis sera**

At day 4 the difference in keratinocyte proliferation and migration was most notable between model wounds exposed to sepsis and healthy sera. To search for possible factors in sera that could explain this difference, we analyzed the levels of cytokines and growth factors in day four serum by multiplex assay. Sera collected on day four from patients with severe sepsis harbored significantly higher concentrations of TNF-α (5.7 vs. 0.7 pg/ml, P < 0.001), IL-6 (24.8 vs. 3.8 pg/ml, P < 0.001), and IL-10 (30.0 vs. 11.9 pg/ml, P = 0.040) than sera collected from healthy controls (Table 2). Of the growth factors, VEGF levels were higher (177.9 vs. 48.1 pg/ml, P = 0.018) and EGF levels were lower (6.5 vs. 115.6 pg/ml, P < 0.001) in severe sepsis serum than in healthy serum (Table 2). There were no significant differences in the levels of IL-4 (5.2 vs. 13.7 pg/ml) or basic fibroblast growth factor (32.2 vs. 21.9 pg/ml) between sepsis and control sera (Table 2).

**Sepsis serum supplemented with TNF-α and EGF enhance keratinocyte migration**

We conducted a wound-healing assay with healthy and sepsis sera containing different concentrations of TNF-α or EGF or EGF receptor inhibitor cetuximab. All concentrations of TNF-α improved cell migration in wounds, both those cultured in healthy and sepsis sera (P < 0.01 in all concentrations) (Fig. 5a). Furthermore, 5 or 10 ng/
ml of EGF in healthy serum significantly enhanced keratinocyte migration ($P = 0.001$), but the addition of 50 ng/ml EGF did not ($P = 0.768$) have a similar effect (Fig. 5b). Sepsis serum with 5 ng/ml EGF significantly ($P = 0.001$) improved cell migration. Higher concentrations (10 and 50 ng/ml) of EGF in sepsis serum did not
have a significant impact on migration. All concentrations of the EGFR inhibitor cetuximab both in healthy or sepsis sera, significantly impaired keratinocyte migration compared to control serum (Fig. 5c). P values are represented in Table 3.

Discussion
In this study, we explored the growth of human keratinocytes (HaCaT) in vitro using sera from severe sepsis patients and healthy controls. We observed that sepsis serum reduced keratinocyte viability, proliferation and migration. Additionally, exosomes excreted from normal fibroblasts treated with sepsis or healthy sera decreased keratinocyte migration. Furthermore, sepsis sera compared to healthy sera contained higher levels of TNF-α, IL-6, IL-10 and VEGF but a lower concentration of EGF. There were no significant differences in levels of bFGF or IL-4 between sepsis and control sera. All concentrations of TNF-α improved cell migration both in healthy sera
and sepsis sera wounds. Low concentrations of EGF in healthy or sepsis sera significantly promoted keratinocyte migration, but migration was suppressed by blockade of the EGF receptor by cetuximab.

Considering the prevalence and economical effects of wound problems in septic patients, wound healing in sepsis is a poorly studied subject. To our knowledge, this is the first report presenting in vitro observations of the retarding effect of human sepsis serum on keratinocyte viability, migration, and proliferation. There are a few animal studies suggesting wound healing is impaired in sepsis [5, 7, 9]. This study is also a continuation to our previous research of human abdominal skin blister wounds, in which we showed that the restoration of epidermal barrier function was lower in patients with severe sepsis than in healthy controls [8].

The role of exosomes in intercellular signaling of skin tissue has recently been analyzed in animal models. Human fibroblast derived exosomes promoted keratinocyte proliferation, migration and wound closure in diabetic mice [38]. Similarly, rat burn wounds treated with mesenchymal stem cell (MSC) derived exosomes enhanced proliferation of skin cells and wound re-epithelialization [29]. We expected to see differences in keratinocyte migration between wounds incubated with exosomes from NF cultured in sepsis or healthy sera media. However, exosomes from NF cultured under both conditions clearly prevented the migration of keratinocytes. One explanation could be the resting state of these locally established NFs. Other studies have shown that with the help of exosomes, transplanted stem and progenitor cells use paracrine signaling to modify recipient cell protein production and gene expression in response to local environmental factors thus accelerating wound healing [20, 29, 39–43]. Thus exploring the contents of exosomes and using exosomes from more dynamic cells, such as MSCs, in both 2D and 3D cultures might give a broader perspective of their role in keratinocyte migration during the wound healing process.

Our results show that the lower amount of EGF is associated with the reduced cell proliferation, viability and migration of keratinocytes incubated with sepsis serum compared to healthy serum. Members of the EGF and FGF families as well as hepatocyte and insulin-like growth factors play a leading role in skin epithelialization during wound healing [13, 44]. Independent of the stimulant, keratinocyte migration seems to be universally conveyed through the EGF receptor; signaling through EGFR promotes keratinocyte migration in vitro [45]. Heparin-binding EGF-like growth factor (HB-EGF) accelerated keratinocyte migration, rather than proliferation in skin wound healing in a mouse model and seemed to be the predominant growth factor in epithelialization [46]. Similarly, the expression of HB-EGF in human keratinocytes

| Serum          | Cytokine | Amount of cytokine | Number of wounds | Mean % (SD) | P value |
|---------------|----------|--------------------|------------------|-------------|---------|
| Healthy (control) | –        | –                  | 8                | 61 (15)     |         |
| Sepsis (control) | –        | –                  | 8                | 75 (20)     |         |
| Healthy        | TNF-α    | 5 ng/ml            | 8                | 14 (15)     | <0.001  |
| Sepsis         | TNF-α    | 5 ng/ml            | 7                | 44 (19)     | 0.009   |
| Healthy        | TNF-α    | 10 ng/ml           | 7                | 13 (15)     | <0.001  |
| Sepsis         | TNF-α    | 10 ng/ml           | 5                | 30 (20)     | 0.02    |
| Healthy        | TNF-α    | 50 ng/ml           | 6                | 7 (16)      | 0.002   |
| Sepsis         | TNF-α    | 50 ng/ml           | 5                | 16 (18)     | 0.005   |
| Healthy        | EGF      | 5 ng/ml            | 6                | 0 (0)       | 0.001   |
| Sepsis         | EGF      | 5 ng/ml            | 8                | 2 (5)       | 0.001   |
| Healthy        | EGF      | 10 ng/ml           | 8                | 9 (17)      | 0.001   |
| Sepsis         | EGF      | 10 ng/ml           | 6                | 72 (57)     | 0.301   |
| Healthy        | EGF      | 50 ng/ml           | 4                | 51 (59)     | 0.768   |
| Sepsis         | EGF      | 50 ng/ml           | 6                | 77 (39)     | 0.887   |
| Healthy        | EGF inhibitor | 1 µg/ml       | 7                | 84 (24)     | 0.037   |
| Sepsis         | EGF inhibitor | 1 µg/ml       | 7                | 96 (7)      | 0.008   |
| Healthy        | EGF inhibitor | 10 µg/ml      | 5                | 95 (11)     | 0.001   |
| Sepsis         | EGF inhibitor | 10 µg/ml      | 6                | 106 (10)    | 0.005   |
| Healthy        | EGF inhibitor | 50 µg/ml      | 7                | 95 (4)      | 0.001   |
| Sepsis         | EGF inhibitor | 50 µg/ml      | 7                | 99 (2)      | 0.001   |

Healthy serum samples are compared to healthy control serum and sepsis serum samples to sepsis control serum. Significant P values are in italic.
triggered a migratory phenotype in partial-thickness wounding of human skin [47]. Application of EGF on wounds in vitro and in vivo had beneficial effects on skin wound healing [48, 49].

Sepsis sera contained higher levels of TNF-α, IL-6, IL-10 and VEGF compared to controls. TNF-α and IL-6 can indirectly induce keratinocyte migration via stimulating production of pro-mitogenic FGF-7, also known as keratinocyte growth factor, from fibroblasts [50]. However, according to our experiments the higher level of TNF-α in sepsis serum is not the reason for impaired keratinocyte migration and wound healing, in contrast to previous studies [51, 52]. Our research supports the suggestion of Sommer et al. [9] that normal TNF-α concentration locally enhances wound repair in sepsis. TNF-α is the primary inflammatory mediator in sepsis as it regulates other downstream cytokines such as IL-6 and IL-10 [53]. IL-6 participates only indirectly in keratinocyte migration: it mainly promotes collagen deposition and angiogenesis in cutaneous wound healing [54–57]. VEGF and its receptor primarily induce angiogenesis but have some influence on keratinocyte migration and proliferation as well [13, 16]. IL-10 has positive effects on wound closure, granulation tissue formation and neovascularization mainly because it improves VEGF expression [58]. Fibroblast growth factor levels are elevated in acute wound fluid and especially bFGF increases keratinocyte motility in re-epithelialization [16]. In our study we could not detect any significant difference in serum concentrations of bFGF between sepsis patients and controls, which suggests that bFGF has a minor role in keratinocyte migration in sepsis. IL-4 participates in normal wound healing by stimulating extracellular matrix synthesis [59] but does not seem to be involved in keratinocyte migration.

As stated earlier, epithelial wound healing in sepsis is affected by a complex mixture of various interacting signaling molecules. To better understand the mechanisms behind impaired wound healing in sepsis, further extensive studies are needed.

Conclusions
In this study we show that human keratinocyte migration, proliferation, and viability were decreased in cultures treated with serum from patients with severe sepsis. Exosomes derived either from healthy or sepsis sera treated fibroblasts inhibited keratinocyte migration. Sepsis sera supplemented with EGF improved and EGF receptor inhibition significantly reduced keratinocyte migration both in healthy and sepsis wounds. Taken together, the net effect of serum on keratinocytes depends on the balance and interplay of various mediators.

Abbreviations
APACHE II: acute physiology and chronic health evaluation II; bFGF: basic fibroblast growth factor; BrdU: 5-bromo-2'-deoxyuridine; DMEM: Dulbecco's modified Eagle's medium; EGF: epithelial growth factor; EGF-R: epithelial growth factor receptor; FBS: fetal bovine serum; FGF: fibroblast growth factor; HA-KT: human adult low-calcium high-temperature keratinocytes; IL: interleukin; MTT: 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NF: normal fibroblast; SD: standard deviation; SOFA: sequential organ failure assessment; TNF-α: tumor necrosis factor α; VEGF: vascular endothelial growth factor.

Authors’ contributions
HJ, MK, FG, SS, VK, TS, and TA designed the study. MK and FG collected the data. HJ and MK performed the laboratory work with the help of SS, JK, MR, TK, and KHH. HJ and MK carried out the measurements and performed the statistical analyses. TS and KHH provided the laboratory facilities. HJ drafted the manuscript with MK, VK, TS, and TA. All authors read and approved the final manuscript.

Author details
1 Research Group of Surgery, Anesthesia and Intensive Care, Oulu University Hospital, P.O. Box 21, 90029 Oulu, Finland. 2 Cancer and Translational Medicine Research Unit, Faculty of Medicine, Medical Research Center Oulu, University of Oulu, P.O. Box 5281, 90014 Oulu, Finland. 3 Research Group of Biomedicine, Faculty of Biochemistry and Molecular Medicine, University of Oulu, P.O. Box 5000, Oulu 90014, Finland. 4 Research Unit of Biomedicine, Faculty of Medicine and Biocenter of Oulu, University of Oulu, P.O. Box 5000, Oulu 90014, Finland. 5 Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Collegium Maius, Fredry 10, 61–701 Poznan, Poland. 6 Research Group of Oral Health Sciences, Oulu University Hospital, Medical Research Center Oulu, University of Oulu, P.O. Box 5000, Oulu 90014, Finland.

Acknowledgements
We would like to thank study nurses Sinikka Sälkiö, RN and Tarja Lamberg, RN for screening patients and obtaining serum samples. We are grateful to Timo Kaakinen, MD Ph.D., who helped with the statistical analysis. We also thank Mrs. Maja-Leena Lehtonen for expert technical assistance in the laboratory.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Ethics approval and consent to participate
This study protocol was approved by The Regional Ethics Committee of the Northern Ostrobothnia Hospital District and written informed consent was obtained from each patient or their next of kin.

Funding
This study was supported by grants from the Medical Research Center of Oulu, University of Oulu Graduate School, the Finnish Medical Foundation, and the Finnish Cultural Foundation, Lapland Regional Fund.

Received: 16 September 2016 Accepted: 14 December 2016 Published online: 13 January 2017

References
1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J, Ramsay G. 2001 Sepsis, organ failure assessment; TNF-α: tumor necrosis factor α; VEGF: vascular endothelial growth factor.

Authors’ contributions
HJ, MK, FG, SS, VK, TS, and TA designed the study. MK and FG collected the data. HJ and MK performed the laboratory work with the help of SS, JK, MR, TK, and KHH. HJ and MK carried out the measurements and performed the statistical analyses. TS and KHH provided the laboratory facilities. HJ drafted the manuscript with MK, VK, TS, and TA. All authors read and approved the final manuscript.

Author details
1 Research Group of Surgery, Anesthesia and Intensive Care, Oulu University Hospital, P.O. Box 21, 90029 Oulu, Finland. 2 Cancer and Translational Medicine Research Unit, Faculty of Medicine, Medical Research Center Oulu, University of Oulu, P.O. Box 5281, 90014 Oulu, Finland. 3 Research Group of Biomedicine, Faculty of Biochemistry and Molecular Medicine, University of Oulu, P.O. Box 5000, Oulu 90014, Finland. 4 Research Unit of Biomedicine, Faculty of Medicine and Biocenter of Oulu, University of Oulu, P.O. Box 5000, Oulu 90014, Finland. 5 Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Collegium Maius, Fredry 10, 61–701 Poznan, Poland. 6 Research Group of Oral Health Sciences, Oulu University Hospital, Medical Research Center Oulu, University of Oulu, P.O. Box 5000, Oulu 90014, Finland.

Acknowledgements
We would like to thank study nurses Sinikka Sälkiö, RN and Tarja Lamberg, RN for screening patients and obtaining serum samples. We are grateful to Timo Kaakinen, MD Ph.D., who helped with the statistical analysis. We also thank Mrs. Maja-Leena Lehtonen for expert technical assistance in the laboratory.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Ethics approval and consent to participate
This study protocol was approved by The Regional Ethics Committee of the Northern Ostrobothnia Hospital District and written informed consent was obtained from each patient or their next of kin.

Funding
This study was supported by grants from the Medical Research Center of Oulu, University of Oulu Graduate School, the Finnish Medical Foundation, and the Finnish Cultural Foundation, Lapland Regional Fund.

Received: 16 September 2016 Accepted: 14 December 2016 Published online: 13 January 2017

References
1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS Interna-
4. Barriero SL, Lowry SF. An overview of mortality risk prediction in sepsis. Crit Care Med. 1995;23:376–93.
5. Ricco RM, Ripamonti R, Burns AL, Gamelli RL, DiPietro LA. The effect of sepsis on wound healing. J Surg Res. 2002;102:193–7.
6. Pink MP, Delahunty RL. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care. 2005;9:177–96.
7. Lin M, Marti G, Dieb R, Wang J, Ferguson M, Quaiser R, Bonde P, Duncan M, Harmon J. Delivery of plasmid DNA expression vector for keratinocyte growth factor-I by using electroporation to improve cutaneous wound healing in a septic rat model. Wound Repair Regeneration. 2006;14:618–24.
8. Koskela M, Gaddnas F, Ala-Kokko T, Laurila JJ, Saarnio J, Oikarinen A, Kouvankangas V. Epidermal wound healing in severe sepsis and septic shock in humans. Crit Care. 2009;13:R100–1.
9. Sommer K, Sander AL, Albig M, Weber R, Heinrich D, Frank J, Marzi I, Jakob H. Delayed wound repair in sepsis is associated with reduced local pro-inflammatory cytokine expression. PLoS ONE. 2013;8:e73992.
10. Gaddnas F, Koskela M, Kouvankangas V, Laurila J, Saarnio J, Risteli J, Oikarinen A, Ala-Kokko T. Skin collagen synthesis is depressed in patients with severe sepsis. Anesth Analg. 2010;111:156–63.
11. Santoro MM, Gaudino G. Cellular and molecular facets of keratinocyte reepithelialization during wound healing. Exp Cell Res. 2005;305:274–86.
12. Peplow PV, Chatterjee MP. A review of the influence of growth factors and cytokines in vitro human keratinocyte migration. Cytokine. 2013;62:1–21.
13. Seager MA, Paller AS. The roles of growth factors in keratinocyte migration. Adv Wound Care. 2015;4:213–24.
14. Martin P. Wound healing—aiming for perfect skin regeneration. Science. 1997;276:75–81.
15. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83:835–70.
16. Barrientos S, Stejadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585–601.
17. Gorden P, Carpenter JL, Cohen S, Orci L. Epidermal growth factor: activity controls the sorting of the epidermal growth factor receptor and the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1978;75:3025–9.
18. Pan BT. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1985;101:942–8.
19. Felder S, Miller K, Moehren G, Ullrich A, Schlessinger J, Hopkins CR. Kinase association in human fibroblasts. Proc Natl Acad Sci USA. 1978;75:5025–9.
20. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteom. 2010;73:1907–20.
21. Azevedo LCP, Janiszewski M, Pontieri V, Pedro MDA, Bassi E, Tucci PJF, Launder FRM. Platelet-derived exosomes from septic shock patients induce microvascular dysfunction. Crit Care. 2007;11:R120.
22. Love RA, Ascierto PA, Massari F, Zhou Q, Baiocchi G, Berardi R, Piovan M, Marciani MG, Landi L, Picardi E, et al. J Transl Med  (2017) 15:11
23. Zheng B, Wang M, Gong A, Zhang X, Wu X, Zhu Y, Shi H, Wu L, Zhu W, Qian H, Xu W. HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells. 2015;33:2158–68.
24. Gaddnas F, Koskela M, Kouvankangas V, Risteli J, Oikarinen A, Laurila J, Saarnio J, Ala-Kokko T. Markers of collagen synthesis and degradation are increased in serum in severe sepsis: a longitudinal study of 44 patients. Crit Care. 2009;13:R83.
25. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent J, Levy MM. Surviving sepsis campaigns guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–73.
26. Van Gent F, Nijkamp J, Bogers AJC, Schipper LS, Vegter HR, Groothuis MG. Heparin-binding EGF-like growth factor promotes epithelial-mesenchymal transition in human keratinocytes. J Invest Dermatol. 2012;132:2148–57.
27. Brown GL, Nanney LB, Griffer J, Cramer AB, Yancey JM, Curtisinger LJ, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med. 1989;321:76–9.
49. Matsumoto Y, Kuroyanagi Y. Development of a wound dressing composed of hyaluronic acid sponge containing arginine and epidermal growth factor. J Biomater Sci Polym Ed. 2010;21:715–26.
50. Brauchle M, Angermeyer K, Hübner G, Werner S. Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene. 1994;9:3199–204.
51. Cooney R, Iocono J, Maish G, Smith JS, Ehrlich P. Tumor necrosis factor mediates impaired wound healing in chronic abdominal sepsis. J Trauma. 1997;42:415–20.
52. Maish GO, Shumate ML, Ehrlich HP, Cooney RN. Tumor necrosis factor binding protein improves incisional wound healing in sepsis. J Surg Res. 1998;78:108–17.
53. Winning J, Claus RA, Huse K, Bauer M. Molecular biology on the ICU. From understanding to treating sepsis. Minerva Anestesiol. 2006;72:255–67.
54. Gallucci RM, Sugawara T, Yucesoy B, Berryann K, Simeonova PP, Matheson JM, Luster M. Interleukin-6 treatment augments cutaneous wound healing in immunosuppressed mice. J Interf Cytok Res. 2001;21:603–9.
55. Sugawara T, Gallucci RM, Simeonova PP, Luster M. Regulation and role of interleukin 6 in wounded human epithelial keratinocytes. Cytokine. 2001;15:328–36.
56. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N. Essential involvement of IL-6. J Leukoc Biol. 2003;73:713–21.
57. Gallucci RM, Sloan DK, Heck JM, Murray AR, O’Dell SJ. Interleukin 6 indirectly induces keratinocyte migration. J Invest Dermatol. 2004;122:764–72.
58. Balaji S, Moles CM, Bhattacharya SS, LeSaint M, Dharmiya Y, Le LD, King A, Kidd M, Bousso MF, Shaaban A, Crombleholme TM, Bolyky P, Keswani SG. Comparison of interleukin ten homologs on dermal wound healing using a novel human skin ex vivo organ culture model. J Surg Res. 2014;190:358–66.
59. Salmon-Ehr V, Ramont L, Godeau G, Birembaut P, Guenounou M, Bernard P, Maquart F. Implication of interleukin-4 in wound healing. Lab Invest. 2000;80:1337–43.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit